VEGF-C, neuropilin-2, and FOXC2 polymorphisms have been identified in patients with breast cancer-related lymphedema (BCRL), suggesting that baseline differences in VEGFR3 activation or lymphatic function may contribute to the risk of developing post-surgical lymphedema [90,91]. Here, FOXC2 is linked to lymphedema.